CML, or Chronic Myeloid Leukemia, is a type of blood cancer that originates in the bone marrow and affects the blood-forming cells, leading to an overproduction of white blood cells. As more than 95% of CML cases are Philadelphia chromosome-positive (Ph+ CML), this condition arises due to a genetic mutation that creates the BCR-ABL1 fusion gene, resulting in the production of abnormal proteins that stimulate uncontrolled cell growth.

Effective management of CML has advanced significantly over the past two decades, allowing many patients to maintain a near-normal life expectancy. Targeted therapy options, particularly tyrosine kinase inhibitors (TKIs), play a pivotal role in treatment. These medications work by inhibiting the BCR-ABL protein to control leukemic cell proliferation.

Collaboration with healthcare providers is crucial, as treatment goals typically include achieving normal blood cell counts and minimizing the BCR-ABL protein levels. Resources like the "Doctor Discussion Guide" aid patients in navigating treatment conversations, fostering a supportive healthcare partnership to combat CML effectively.